Upadacitinib for treating severe rheumatoid arthritis

  • Technology appraisal guidance
  • TA665
  • Published: 
Download guidance (PDF)

Update information

December 2020: Recommendation 1.4 updated to clarify when upadacitinib can be used as monotherapy.

Minor changes since publication

January 2022: Link to NICE Pathway removed.

November 2021: We added a link to the technology appraisal guidance on upadacitinib for treating moderate rheumatoid arthritis.

ISBN: 978-1-4731-3937-4